Coronavirus COVID-19 Outbreak – What's New

William M. Detmer, MD, supported by the Unbound Medicine Team

Updated: Monday, October 26, 2020 09:25 ET

COVID-19 Cases

Around the Globe

New Cases in Countries with Highest COVID-19 Activity
New Cases in Countries with Highest COVID-19 Activity

Recent Confirmed Cases in countries with the highest reported COVID-19 activity (India, United States, Brazil, Argentina, Colombia, France, Peru, Mexico, Russia, UK). Note that the left axis is linear rather than logarithmic and representsthe number of cases reported (rolling 3-day average) to the European CDC by each country.

Click for Live Updates.

Data sources: European CDC. Our World in Data.

Total and New COVID-19 Cases — from European CDC

Cases

Deaths

October 26, 2020

Total

New

Total

New

United States

8,636,165

59,440

225,230

331

France

1,138,507

52,010

34,761

116

India

7,909,959

45,148

119,014

480

Italy

525,782

21,273

37,338

128

UK

873,800

19,790

44,896

151

Russia

1,513,877

16,710

26,050

229

Brazil

5,394,128

13,493

157,134

231

Poland

253,688

11,742

4,438

87

Netherlands

290,925

10,194

7,036

27

Argentina

1,090,576

9,253

28,896

283

Germany

437,866

8,685

10,056

24

Colombia

1,015,885

8,174

30,154

154

Czechia

258,097

7,300

2,201

124

Iran

568,896

6,191

32,616

296

Ukraine

343,489

6,079

6,391

102

Other countries

12,888,533

87,776

389,024

1,317

TOTAL

43,140,173

383,258

1,155,235

4,080

European Centre for Disease Prevention and Control.[1]

Note: ECDC statistics are reported daily. See other sources for hour-by-hour updates.

Statistics may differ from other reporting agencies.

COVID-19 Outbreak Map by Johns Hopkins CSSE – Updated Hourly
Coronavirus 2019 COVID-19 Outbreak Map

Click one of the links below to see the latest.
Desktop | Mobile
Source: Johns Hopkins Center for Systems Science and Engineering (CSSE).[2]

In the United States

  • As of October 19 12:15 ET (CDC)
    • Total cases: more than 8.55 million in all 50 states
    • Deaths: more than 224,200 reported
U.S. Key COVID-19 Metrics: October 26
U.S. Key COVID-19 Metrics - What's New

Key COVID-19 metrics in the United States since April 1. Dark lines represent 7-day averages.

Click for Live Updates.

Source: The COVID-19 Tracking Project[3]

U.S. Deaths and Cases by State and County
Coronavirus deaths in US by State and County

Aggregate data from the Centers for Disease Control and Prevention (CDC) and state- and local-level public health agencies. County-level data is confirmed by referencing state and local agencies directly. Confirmed cases and deaths reflect cumulative totals since January 22nd, 2020.

Click for Live Updates.

Source: USAFacts.org.[4]

U.S. States with the Most COVID-19 Activity

October 26, 2020

Cases

Deaths

State

Total

Last 7d

Per 100k

Total

Last 7d

Per 100k

Texas

858,071

37,508

2,990

17,456

472

58

Illinois

374,907

31,517

2,942

9,751

299

59

Wisconsin

205,139

29,912

3,529

1,803

215

0

California

892,810

28,355

2,257

17,311

412

81

Florida

766,305

23,287

3,598

16,417

500

43

Tennessee

244,087

17,948

3,605

3,100

197

38

Michigan

175,612

16,493

1,758

7,522

205

128

Ohio

195,806

15,581

1,675

5,206

139

91

North Carolina

258,292

14,567

2,488

4,144

215

70

Indiana

160,454

14,477

2,398

4,118

200

77

Missouri

169,495

12,799

2,767

2,805

223

0

Pennsylvania

192,622

11,679

1,504

8,654

188

74

Alabama

183,276

11,614

3,750

2,866

78

41

Minnesota

132,122

11,032

2,355

2,381

164

14

Oklahoma

122,102

10,478

3,097

1,252

91

51

Georgia

349,605

10,221

3,323

7,808

201

32

U.S. Centers for Disease Control.

What’s New Elsewhere

Feedback

Your feedback is appreciated!

Share this page

Share by emailShare by FacebookShare by Twitter

References

  1. Situation update worldwide. European Centre for Disease Prevention and Control. [https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases]
  2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020.  [PMID:32087114]
  3. Nationwide COVID-19 Metrics Since April 1. The COVID Tracking Project. [https://covidtracking.com/data/charts/us-all-key-metrics]
  4. Coronavirus Locations: COVID-19 Map by County and State. USAFacts.org. [https://usafacts.org/visualizations/coronavirus-covid-19-spread-map/]
  5. Abbasi J. The Promise and Peril of Antibody Testing for COVID-19. JAMA. 2020.  [PMID:32301958]
  6. Angulo FJ, Finelli L, Swerdlow DL. Reopening Society and the Need for Real-Time Assessment of COVID-19 at the Community Level. JAMA. 2020.  [PMID:32412582]
  7. Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020;369:m1996.  [PMID:32471884]
  8. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 2020.  [PMID:32445440]
  9. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020.  [PMID:32412710]
  10. Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020.  [PMID:32492293]
  11. Brooks JT, Butler JC, Redfield RR. Universal Masking to Prevent SARS-CoV-2 Transmission-The Time Is Now. JAMA. 2020.  [PMID:32663243]
  12. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed 27 June 2020.
  13. Carfì A, Bernabei R, Landi F, et al. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020.  [PMID:32644129]
  14. Cavalcanti AB et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. July 23, 2020 DOI: 10.1056/NEJMoa2019014
  15. Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020.  [PMID:32434946]
  16. Chen WH, Strych U, Hotez PJ, et al. The SARS-CoV-2 Vaccine Pipeline: an Overview. Curr Trop Med Rep. 2020.  [PMID:32219057]
  17. Chu DK, Akl EA, Duda S, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020.  [PMID:32497510]
  18. Coronavirus Disease 2019 (COVID-19) Situation Reports. World Health Organization. [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-...]
  19. Coronavirus in the U.S.: Latest Map and Case Count. New York Times. [https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html]
  20. Dufort EM, Koumans EH, Chow EJ, et al. Multisystem Inflammatory Syndrome in Children in New York State. N Engl J Med. 2020.  [PMID:32598830]
  21. Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020.  [PMID:32558485]
  22. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020.  [PMID:32598831]
  23. Gao Q, Bao L, Mao H, et al. Rapid development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020.  [PMID:32376603]
  24. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020.  [PMID:32379955]
  25. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020.  [PMID:32459919]
  26. Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020.  [PMID:32275812]
  27. Halfmann PJ, Hatta M, Chiba S, et al. Transmission of SARS-CoV-2 in Domestic Cats. N Engl J Med. 2020.  [PMID:32402157]
  28. Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med. 2020.  [PMID:32692365]
  29. Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020.  [PMID:32401715]
  30. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020.  [PMID:32663912]
  31. Kirkcaldy RD, King BA, Brooks JT. COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions. JAMA. 2020.  [PMID:32391855]
  32. Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science. 2020;367(6485):1412-1413.  [PMID:32217705]
  33. Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020.  [PMID:32492084]
  34. Lurie N, Saville M, Hatchett R, et al. Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020.  [PMID:32227757]
  35. Mahase E. Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds. BMJ. 2020;369:m2422.  [PMID:32546467]
  36. Mahase E. Covid-19: What is the evidence for cloth masks? BMJ. 2020;369:m1422.  [PMID:32265341]
  37. Mehra MR, Desai SS, Ruschitzka F, et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020.  [PMID:32450107]
  38. Moore BJB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020.  [PMID:32303591]
  39. Morawska L, Milton DK. It is Time to Address Airborne Transmission of COVID-19. Clin Infect Dis. 2020.  [PMID:32628269]
  40. NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19 [News]. US National Institute of Allergy and Infectious Diseases. April 29, 2020. [https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-...]
  41. NIH clinical trial of investigational vaccine for COVID-19 begins: study enrolling Seattle-based healthy adult volunteers [News]. March 16, 2020. [https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investiga...]
  42. Norrie JD. Remdesivir for COVID-19: challenges of underpowered studies. Lancet. 2020;395(10236):1525-1527.  [PMID:32423580]
  43. Petherick A. Developing antibody tests for SARS-CoV-2. Lancet. 2020;395(10230):1101-1102.  [PMID:32247384]
  44. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020.  [PMID:32645347]
  45. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020.  [PMID:32678530]
  46. Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission. U.S. Centers for Disease Control and Prevention. [https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-...]
  47. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. 2020.  [PMID:32392282]
  48. Schaffer DeRoo S, Pudalov NJ, Fu LY. Planning for a COVID-19 Vaccination Program. JAMA. 2020.  [PMID:32421155]
  49. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020.  [PMID:32374370]
  50. Shi J, Wen Z, Zhong G, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science. 2020.  [PMID:32269068]
  51. Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial. Ann Intern Med. 2020.  [PMID:32673060]
  52. Stringhini S et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. June 11, 2020. S0140-6736(20)31304-0. [https://doi.org/10.1016/]
  53. Studdert DM, Hall MA. Disease Control, Civil Liberties, and Mass Testing - Calibrating Restrictions during the Covid-19 Pandemic. N Engl J Med. 2020.  [PMID:32272003]
  54. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849.  [PMID:32409561]
  55. Torjesen I. Covid-19: Hydroxychloroquine does not benefit hospitalised patients, UK trial finds. BMJ. 2020;369:m2263.  [PMID:32513810]
  56. Treon SP, Castillo J, Skarbnik AP, et al. The BTK-inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients. Blood. 2020.  [PMID:32302379]
  57. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020.  [PMID:32410760]
  58. Walker PGT, Whittaker C, Watson OJ, et al. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. Science. 2020.  [PMID:32532802]
  59. Wang X, Ferro EG, Zhou G, et al. Association Between Universal Masking in a Health Care System and SARS-CoV-2 Positivity Among Health Care Workers. JAMA. 2020.  [PMID:32663246]
  60. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-1578.  [PMID:32423584]
  61. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020.  [PMID:32648899]
  62. Woloshin S, Patel N, Kesselheim AS. False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications. N Engl J Med. 2020.  [PMID:32502334]

Coronavirus COVID-19 Outbreak – What's Newis the Relief Central Word of the day!

Last updated: October 26, 2020